Dysmenorrhea: NSAIDs, Hormonal Suppression, and Treatment Selection

Determine whether pain is primary or secondary

Primary dysmenorrhea usually begins around menses with cramping and may be accompanied by nausea, diarrhea, headache, or fatigue. Progressive pain, noncyclic pelvic pain, pain with intercourse, abnormal bleeding, infertility, fever, or lack of response to adequate treatment suggests evaluation for endometriosis, adenomyosis, fibroids, PID, pregnancy-related pathology, or another cause. The diagnosis is primarily clinical when the presentation is classic and no red flags are present; indiscriminate imaging is not necessary for everyone (Cieri-Hutcherson, 2026).

First-line medication: NSAIDs

NSAIDs reduce endometrial prostaglandin synthesis and uterine pain. For predictable primary dysmenorrhea, start an appropriate NSAID one to two days before anticipated bleeding or at symptom onset, then continue during peak symptom days. A product-label example is naproxen SODIUM 550 mg initially, followed by either 275 mg every 6–8 hours as needed or 550 mg every 12 hours; do not exceed 1,375 mg on day one or 1,100 mg/day thereafter. Distinguish naproxen sodium strengths from naproxen-base products, which are not interchangeable milligram-for-milligram. Screen for renal disease, ulcer/GI bleeding, concomitant anticoagulants, pregnancy considerations, hypertension, and cardiovascular risk; use the lowest effective dose for the shortest practical course (National Library of Medicine, 2026; Cieri-Hutcherson, 2026).

Hormonal suppression when NSAIDs are unsuitable or inadequate

Combined oral contraception can reduce ovulation, endometrial growth, and prostaglandin generation and provides pregnancy prevention when desired. Continuous or extended active-pill schedules may reduce menstrual symptoms and scheduled bleeding. Progestin-only methods, including depot medroxyprogesterone and selected LNG-IUDs, are alternatives when estrogen is contraindicated or not desired. An LNG-IUD requires procedure counseling, and DMPA requires discussion of delayed fertility return and bone-related risk. Choice should account for baseline bleeding, comorbidities, contraception goals, cost, and the U.S. MEC classification (Cieri-Hutcherson, 2026; Vernon, 2026).

Monitoring and treatment failure

Record functional impact, school or work absence, pain severity, menstrual pattern, adverse effects, and adherence. A short planned trial across several cycles allows a fair assessment. Failure after adequate NSAIDs and hormonal treatment, or onset of atypical symptoms, warrants investigation for secondary dysmenorrhea rather than endless dose escalation. Discuss heat, exercise as tolerated, and patient-directed nonpharmacologic methods as adjuncts without substituting them for needed evaluation (Cieri-Hutcherson, 2026).

An adequate NSAID trial is scheduled, not occasional rescue

An adequate primary-dysmenorrhea NSAID trial begins before or at symptom onset and covers the highest-symptom days, without combining NSAIDs. The product-labeled naproxen SODIUM schedule is 550 mg initially, then 275 mg every 6–8 hours as needed or 550 mg every 12 hours, with maximum totals of 1,375 mg on day one and 1,100 mg on later days. Avoid treating these as equivalent to naproxen-base tablet strengths. Ibuprofen is another established option, selected and limited according to individual kidney, GI, cardiovascular, pregnancy and medication risks. Failure despite correctly timed treatment, or a concurrent desire for menstrual suppression/contraception, should prompt diagnostic or hormonal-option review rather than reflexively escalating the NSAID dose (National Library of Medicine, 2026; Cieri-Hutcherson, 2026).

Identify failure of the primary-dysmenorrhea diagnosis

Reassess after approximately three treated cycles for adherence, pain scores, missed activities, adverse effects, and whether pain is confined to menstrual days. Progressive pain, dyspareunia, abnormal bleeding, fever, or pain outside menses merits evaluation for endometriosis, infection, pregnancy-related problems, or structural disease. NSAID failure should trigger diagnostic reconsideration rather than indefinite opioid substitution (Cieri-Hutcherson, 2026).

Clinical application

A 20-year-old with predictable day-1 cramps and no red flags has tried 200 mg ibuprofen only after pain becomes severe. Compare scheduled appropriately dosed NSAID treatment starting before expected menses with immediate hormonal suppression; because she also desires contraception and fewer periods, a continuous combined regimen may provide two benefits if estrogen eligible. Record baseline missed-work days and reassess after three cycles. New dyspareunia or noncyclic pain would shift toward a secondary-cause evaluation (Cieri-Hutcherson, 2026).

High-yield distinctions

NSAIDs work best when taken early rather than after severe pain is established. Hormonal contraception can treat dysmenorrhea even when pregnancy prevention is not the principal goal. Persistent pain despite appropriate first-line care is a prompt to reconsider the diagnosis.

Related YourDNP Resources

Pharmacology learning hub · Combined hormonal contraception · Progestin-only contraception · Heavy menstrual bleeding · Pelvic inflammatory disease

---

---

References

Cieri-Hutcherson, N. E. (2026). Menstruation-related disorders and menopause. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 50). McGraw Hill.

National Library of Medicine. (2026). Naproxen sodium tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9eb8c40-85d9-4c8e-9523-a21d3591260f

Vernon, V. P. (2026). Contraception. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 49). McGraw Hill.